QBie™ Spotlight: Blake Insomnia Therapeutics, Inc. (OTCQB: BKIT)
QBie™ Spotlight sits down with Birger Jan Olsen, CEO of Blake Insomnia Therapeutics, Inc. (OTCQB: BKIT), to discuss one of the OTCQB’s newest additions. BKIT joined the OTCQB on October 26th of this year.
What does Blake Insomnia Therapeutics do?
Birger Jan Olsen (CEO – OTCQB: BKIT): “Blake Insomnia Therapeutics Inc. is a pharmaceutical company dedicated to improving nighttime and daytime quality of life for people with insomnia. Blake Insomnia’s lead product candidate Zleepax™ offers a new way of treating stress-related insomnia. It works by reducing physical stress symptoms that inhibit sleep at night, without producing the unwanted side effects typically associated with hypnotics. This gives Zleepax™ the potential to become any doctor’s first line therapy for treating ordinary stress-related insomnia.”
What is the next big goal BKIT is trying to accomplish/what should we keep an eye out for?
Birger Jan Olsen: “Blake Insomnia’s first objective is to raise $5 million as a seed investment allowing the company to conduct the first phase IIa clinical study 2017 to demonstrate Zleepax™ efficacy in the treatment of stress-related insomnia.”
Why did you join the OTCQB/go public?
Birger Jan Olsen: “We joined the OTCQB to use our stock for raising capital. We felt it was time to get a more diverse pool of investors. We were originally funded by a group of private investors and we want to create a liquidity event for those shareholders. We are seeking to drive visibility to our company in the investment community as we aim to simultaneously gain market visibility by Big Pharma.”
How can members of the microcap community help you?
Birger Jan Olsen: “I would be pleased to connect with other members who have been raising capital from investment firms or gone through a M&A process in order to exchange knowledge. We are also keen on getting in contact with pharma companies that have an interest in our insomnia product.”
Learn more about Blake Insomnia Therapeutics, Inc. (OTCQB: BKIT) on their website: www.blakeinsomnia.com
Blake Insomnia Therapeutics, Inc. can be contacted at: firstname.lastname@example.org
About QBie™ Spotlight:
QBie™ Spotlight is a virtual “welcome interview” for new OTCQB companies. QBie™ Spotlight helps issuers that are new to the OTCQB connect with microcap industry professionals! Learn more about the QBie™ Spotlight HERE.
Disclaimer/Forward Looking Statements:
This Website and its contents are not to be construed, under any circumstances, as an offer to sell or a solicitation to buy or effect transactions in any securities. No investment advice is provided or should be construed to be provided herein. This Website and its owners, employees and affiliates are not, nor do any of them claim to be, registered broker-dealers or registered investment advisors. This Website may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Such forward-looking statements of or concerning the companies mentioned herein are subject to numerous uncertainties and risk factors, including uncertainties and risk factors that may not be set forth herein, which could cause actual results to differ materially from those stated herein. Accordingly, user of this Website are cautioned not to place undue reliance on such forward-looking statements. This Website undertakes no obligation to update any forward-looking statements that may be contained herein.